For the Media
Dr. David Maloney is a member of Fred Hutch's Clinical Research Division and a member of the Lymphoma Program. His laboratory and clinical research is focused on the development of development of new, safe and effective therapies for patients with lymphoid cancers, including lymphomas, leukemias and myeloma. His primary focus is treatments that can enhance anti-cancer immune responses, collectively known as immunotherapies. One strategy uses immune cell products known as antibodies.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.